Shitara Y - Search Results

1

CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.

Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE. Zheng S, et al. Among authors: shitara y. Transplantation. 2013 Mar 27;95(6):821-7. doi: 10.1097/TP.0b013e31827e6ad9. Transplantation. 2013. PMID: 23354298 Free PMC article.

2

Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.

Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE. Zheng S, et al. Among authors: shitara y. Clin Pharmacol Ther. 2012 Dec;92(6):737-45. doi: 10.1038/clpt.2012.175. Epub 2012 Oct 17. Clin Pharmacol Ther. 2012. PMID: 23073208 Free PMC article.

3

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

Shitara Y, Sugiyama Y. Shitara Y, et al. Pharmacol Ther. 2006 Oct;112(1):71-105. doi: 10.1016/j.pharmthera.2006.03.003. Epub 2006 May 22. Pharmacol Ther. 2006. PMID: 16714062 Review.

4

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.

Shitara Y, Hirano M, Sato H, Sugiyama Y. Shitara Y, et al. J Pharmacol Exp Ther. 2004 Oct;311(1):228-36. doi: 10.1124/jpet.104.068536. Epub 2004 Jun 11. J Pharmacol Exp Ther. 2004. PMID: 15194707

5

Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.

Tanii H, Shitara Y, Horie T. Tanii H, et al. Among authors: shitara y. Eur J Clin Pharmacol. 2011 Oct;67(10):1017-25. doi: 10.1007/s00228-011-1042-3. Epub 2011 Apr 15. Eur J Clin Pharmacol. 2011. PMID: 21494765 Clinical Trial.

6

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Shitara Y, et al. J Pharmacol Exp Ther. 2003 Feb;304(2):610-6. doi: 10.1124/jpet.102.041921. J Pharmacol Exp Ther. 2003. PMID: 12538813

7

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.

Hirano M, Maeda K, Shitara Y, Sugiyama Y. Hirano M, et al. Among authors: shitara y. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46. doi: 10.1124/jpet.104.068056. Epub 2004 May 24. J Pharmacol Exp Ther. 2004. PMID: 15159445

8

In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats.

Shitara Y, Hirano M, Adachi Y, Itoh T, Sato H, Sugiyama Y. Shitara Y, et al. Drug Metab Dispos. 2004 Dec;32(12):1468-75. doi: 10.1124/dmd.32.12.. Drug Metab Dispos. 2004. PMID: 15550721

9

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.

Shitara Y, Sato H, Sugiyama Y. Shitara Y, et al. Annu Rev Pharmacol Toxicol. 2005;45:689-723. doi: 10.1146/annurev.pharmtox.44.101802.121444. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822193 Review.

10

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

Hirano M, Maeda K, Shitara Y, Sugiyama Y. Hirano M, et al. Among authors: shitara y. Drug Metab Dispos. 2006 Jul;34(7):1229-36. doi: 10.1124/dmd.106.009290. Epub 2006 Apr 4. Drug Metab Dispos. 2006. PMID: 16595711

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters